Skip to main content
. 2020 Aug 5;47(10):e23421. doi: 10.1002/clc.23421

Figure 2.

Figure 2

Summary of the associations between use of ACEI/ARB and clinical outcomes among patients with COVID‐19. A, Risk of COVID‐19 infection. B, Risk of severe COVID‐19 infection. C, All‐cause death. *severe COVID‐19 or death. ACEI, angiotensin I converting enzyme inhibitor; ARB, angiotensin II receptor blockers; COVID‐19, coronavirus disease 2019